{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:15:35Z","timestamp":1792782935920,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Necmettin Erbakan University","id":[{"id":"https:\/\/ror.org\/013s3zh21","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst growth, kidney enlargement, and decline in renal function. Increasing evidence suggests that inflammatory processes may contribute to disease progression. This study aimed to evaluate the association between tolvaptan use, systemic inflammatory markers, and total kidney volume (TKV) progression in patients with ADPKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 67 patients with ADPKD, including 40 receiving tolvaptan and 27 untreated controls. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), estimated glomerular filtration rate (eGFR), and TKV were evaluated at baseline and after 24 months. Longitudinal changes were assessed using Wilcoxon signed-rank tests and linear mixed-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients receiving tolvaptan were younger and had higher baseline TKV values than untreated patients. During follow-up, NLR, PLR, and SII decreased in the tolvaptan group, whereas these markers increased in untreated patients. eGFR declined in both groups but appeared less pronounced in patients receiving tolvaptan. TKV increased in both groups; however, the percentage increase in TKV was lower among patients receiving tolvaptan. Significant time \u00d7 treatment interactions were observed for NLR, PLR, SII, and TKV. In the non-tolvaptan group, NLR at 24 months showed a significant positive association with TKV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tolvaptan use was associated with differences in longitudinal changes in systemic inflammatory markers and kidney volume progression in ADPKD. Further prospective studies are needed to clarify the clinical relevance of these associations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10157-026-02910-0","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:19:06Z","timestamp":1782379146000},"page":"1539-1546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of tolvaptan on total kidney volume and inflammatory markers in autosomal dominant polycystic kidney disease"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4973-8804","authenticated-orcid":false,"given":"Merve","family":"Oruc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Burak","family":"Ercin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Oruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kultigin","family":"Turkmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Baloglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"2","key":"2910_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.kint.2024.07.010","volume":"107","author":"VE Torres","year":"2025","unstructured":"Torres VE, Ahn C, Barten TRM, Brosnahan G, Cadnapaphornchai MA, Chapman AB, et al. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary. Kidney Int. 2025;107(2):234\u201354.","journal-title":"Kidney Int"},{"issue":"25","key":"2910_CR2","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407\u201318.","journal-title":"N Engl J Med"},{"issue":"5","key":"2910_CR3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","volume":"57","author":"VE Torres","year":"2011","unstructured":"Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3\u20134 Study. Am J Kidney Dis. 2011;57(5):692\u20139.","journal-title":"Am J Kidney Dis"},{"key":"2910_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/DHPS.S338050","volume":"14","author":"R Raina","year":"2022","unstructured":"Raina R, Houry A, Rath P, Mangat G, Pandher D, Islam M, et al. Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Drug Healthc Patient Saf. 2022;14:147\u201359.","journal-title":"Drug Healthc Patient Saf"},{"issue":"2","key":"2910_CR5","doi-asserted-by":"publisher","first-page":"101694","DOI":"10.1016\/j.gendis.2025.101694","volume":"13","author":"C Xue","year":"2026","unstructured":"Xue C, Li X, Zhou C, Mei C, Mao Z. Immune microenvironment in autosomal dominant polycystic kidney disease. Genes Dis. 2026;13(2):101694.","journal-title":"Genes Dis"},{"issue":"6","key":"2910_CR6","doi-asserted-by":"publisher","first-page":"e0131043","DOI":"10.1371\/journal.pone.0131043","volume":"10","author":"JX Zhou","year":"2015","unstructured":"Zhou JX, Fan LX, Li X, Calvet JP, Li X. TNFalpha signaling regulates cystic epithelial cell proliferation through Akt\/mTOR and ERK\/MAPK\/Cdk2 mediated Id2 signaling. PLoS ONE. 2015;10(6):e0131043.","journal-title":"PLoS ONE"},{"issue":"6","key":"2910_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.semnephrol.2019.10.009","volume":"39","author":"M Theodorakopoulou","year":"2019","unstructured":"Theodorakopoulou M, Raptis V, Loutradis C, Sarafidis P. Hypoxia and Endothelial Dysfunction in Autosomal-Dominant Polycystic Kidney Disease. Semin Nephrol. 2019;39(6):599\u2013612.","journal-title":"Semin Nephrol"},{"issue":"1","key":"2910_CR8","doi-asserted-by":"publisher","first-page":"32228","DOI":"10.1038\/s41598-025-15681-7","volume":"15","author":"AZ Sahin","year":"2025","unstructured":"Sahin AZ, Ozdemir O. The effect of tolvaptan on renal progression and systemic inflammation in ADPKD. Sci Rep. 2025;15(1):32228.","journal-title":"Sci Rep"},{"key":"2910_CR9","volume-title":"Health Practice Communiqu\u00e9 (Sa\u011fl\u0131k Uygulama Tebli\u011fi)","year":"2023","unstructured":"Institution RoTSS. In: Institution SS, editor. Health Practice Communiqu\u00e9 (Sa\u011fl\u0131k Uygulama Tebli\u011fi). Ankara: Official Gazette; 2023."},{"issue":"5","key":"2910_CR10","doi-asserted-by":"publisher","first-page":"e0178488","DOI":"10.1371\/journal.pone.0178488","volume":"12","author":"K Sharma","year":"2017","unstructured":"Sharma K, Caroli A, Quach LV, Petzold K, Bozzetto M, Serra AL, et al. Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease. PLoS ONE. 2017;12(5):e0178488.","journal-title":"PLoS ONE"},{"issue":"20","key":"2910_CR11","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930\u201342.","journal-title":"N Engl J Med"},{"issue":"5","key":"2910_CR12","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2215\/CJN.06300615","volume":"11","author":"VE Torres","year":"2016","unstructured":"Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, et al. Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial. Clin J Am Soc Nephrol. 2016;11(5):803\u201311.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"2910_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2025.100988","volume":"7","author":"RD Perrone","year":"2025","unstructured":"Perrone RD, Garbinsky D, Nunna S, Gandhi HK, Fernandes AW, Burgos G, et al. Effectiveness of tolvaptan for autosomal dominant polycystic kidney disease in US clinical practice with comparison to historical control data. Kidney Med. 2025;7(5):100988.","journal-title":"Kidney Med"},{"issue":"9","key":"2910_CR14","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1093\/ndt\/gfaf048","volume":"40","author":"P Geertsema","year":"2025","unstructured":"Geertsema P, Bais T, Kuiken V, Knol MGE, Casteleijn NF, Vart P, et al. The long-term effect of tolvaptan treatment on kidney function and volume in patients with ADPKD. Nephrol Dial Transplant. 2025;40(9):1764\u201374.","journal-title":"Nephrol Dial Transplant"},{"key":"2910_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14186537","author":"V Filiopoulos","year":"2025","unstructured":"Filiopoulos V, Kofotolios I, Vallianou K, Karavasilis E, Ntounas G, Melexopoulou C, et al. Long-term effects of tolvaptan therapy on total kidney volume and renal function in patients with autosomal dominant polycystic kidney disease: a single-center experience. Journal of Clinical Medicine. 2025. https:\/\/doi.org\/10.3390\/jcm14186537.","journal-title":"Journal of Clinical Medicine"},{"issue":"9","key":"2910_CR16","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.34067\/KID.0000000000000525","volume":"5","author":"S Arjune","year":"2024","unstructured":"Arjune S, Lettenmeier K, Todorova P, Spath MR, Majjouti M, Mahabir E, et al. Inflammatory cytokine levels in patients with autosomal dominant polycystic kidney disease. Kidney360. 2024;5(9):1289\u201398.","journal-title":"Kidney360"},{"issue":"2","key":"2910_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40620-021-01062-6","volume":"35","author":"I Capuano","year":"2022","unstructured":"Capuano I, Buonanno P, Riccio E, Amicone M, Pisani A. Therapeutic advances in ADPKD: the future awaits. J Nephrol. 2022;35(2):397\u2013415.","journal-title":"J Nephrol"},{"key":"2910_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11020402","author":"M Rigato","year":"2022","unstructured":"Rigato M, Carraro G, Cirella I, Dian S, Di Vico V, Stefanelli LF, et al. Effects of tolvaptan on oxidative stress in ADPKD: a molecular biological approach. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11020402.","journal-title":"J Clin Med"},{"issue":"2","key":"2910_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1124\/jpet.114.213256","volume":"349","author":"M Aihara","year":"2014","unstructured":"Aihara M, Fujiki H, Mizuguchi H, Hattori K, Ohmoto K, Ishikawa M, et al. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. J Pharmacol Exp Ther. 2014;349(2):258\u201367.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2910_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1445-5994.2010.02404.x","volume":"42","author":"K Turkmen","year":"2012","unstructured":"Turkmen K, Tufan F, Alpay N, Kasikcioglu E, Oflaz H, Ecder SA, et al. Insulin resistance and coronary flow velocity reserve in patients with autosomal dominant polycystic kidney disease. Intern Med J. 2012;42(2):146\u201353.","journal-title":"Intern Med J"},{"key":"2910_CR21","doi-asserted-by":"publisher","DOI":"10.14744\/ijmb.2017.08108","author":"Y Ustundag","year":"2018","unstructured":"Ustundag Y. Relationship between CRP, systemic immune-inflammation index and routine hemogram related inflammatory markers in low grade inflammation. Int J Med Biochem. 2018. https:\/\/doi.org\/10.14744\/ijmb.2017.08108.","journal-title":"Int J Med Biochem"},{"issue":"1","key":"2910_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.medcli.2024.01.026","volume":"163","author":"L Cantarelli","year":"2024","unstructured":"Cantarelli L, Gutierrez Valencia M, Leache Alegria L, Sainz Fernandez LC, Erviti Lopez J, Gutierrez Nicolas F, et al. Long-term effectiveness and safety of tolvaptan in autosomal dominant polycystic kidney disease. Med Clin (Barc). 2024;163(1):1\u20137.","journal-title":"Med Clin (Barc)"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02910-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02910-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02910-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:09:43Z","timestamp":1792012183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02910-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2910"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02910-0","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}